Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
168.00B
Market cap168.00B
Price-Earnings ratio
39.46
Price-Earnings ratio39.46
Dividend yield
5.77%
Dividend yield5.77%
Average volume
27.57M
Average volume27.57M
High today
$29.98
High today$29.98
Low today
$29.80
Low today$29.80
Open price
$29.49
Open price$29.49
Volume
224.14K
Volume224.14K
52 Week high
$30.44
52 Week high$30.44
52 Week low
$23.62
52 Week low$23.62

Stock Snapshot

As of today, Pfizer(PFE) shares are valued at $29.95. The company's market cap stands at 168B, with a P/E ratio of 39.46 and a dividend yield of 5.77%.

During the trading session on 2026-10-29, Pfizer(PFE) shares reached a daily high of $29.98 and a low of $29.80. At a current price of $29.95, the stock is +0.5% higher than the low and still -0.1% under the high.

Trading activity shows a volume of 224.14K, compared to an average daily volume of 27.57M.

The stock's 52-week range extends from a low of $23.62 to a high of $30.44.

The stock's 52-week range extends from a low of $23.62 to a high of $30.44.

PFE News

Simply Wall St 2h
Pfizer Stock Trades At A Premium Despite Its 30% Rebound - Simply Wall St

...

Pfizer Stock Trades At A Premium Despite Its 30% Rebound - Simply Wall St
Zacks 1d
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's ear...

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Simply Wall St 1d
What Is Pfizer Signaling With Its Latest Oncology Trial And FDA Win?

Pfizer (NYSE:PFE) reported that ELREXFIO met its primary endpoint of progression free survival in a pivotal Phase 3 trial in relapsed or refractory multiple mye...

Analyst ratings

62%

of 29 ratings
Buy
27.6%
Hold
62.1%
Sell
10.3%

More PFE News

Benzinga 2d
Pfizer Cancer Therapy Shows Extended Progression-Free Survival in Multiple Myeloma Patients

Pfizer Inc. (NYSE:PFE) on Tuesday released topline results from its Phase 3 MagnetisMM-32 study evaluating Elrexfio (elranatamab) as a monotherapy. • Pfizer st...

Pfizer Cancer Therapy Shows Extended Progression-Free Survival in Multiple Myeloma Patients
24/7 Wall St. 3d
How Much Retirement Income Could $100,000 in These 3 Dividend Stocks Generate?

Three companies in pharmaceuticals, energy, and tobacco operate in entirely different worlds, and that separation is exactly the point for retirees who need the...

How Much Retirement Income Could $100,000 in These 3 Dividend Stocks Generate?
24/7 Wall St. 3d
Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady

Investing Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady Moderna's personalized melanoma vaccine cleared its prima...

Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady
TipRanks 4d
Pfizer Lung Cancer Drug Shows Survival Benefit Despite Trial Failure

Pfizer (PFE) is keeping its experimental lung cancer drug alive despite a failed clinical trial. New data showed that some patients treated with sigvotatug vedo...

Simply Wall St 5d
How Phase 2 Vaccine Results At Pfizer Has Changed Its Investment Story

Pfizer reported detailed Phase 2 data for its 25-valent pneumococcal conjugate vaccine in infants, showing robust immune responses across all 25 serotypes with...

The Motley Fool 5d
Pfizer's Dividend Yield Is One of the Highest in the S&P 500. Here's Why the Dividend Is Safer Than It Might Seem

The S&P 500 is full of quality dividend stocks. But is Pfizer (PFE -1.28%) one of them? On the one hand, the drugmaker has one of the highest yields in the inde...

Pfizer's Dividend Yield Is One of the Highest in the S&P 500. Here's Why the Dividend Is Safer Than It Might Seem
Simply Wall St 6d
Pfizer Showcases IDWeek Data, Is The Stock Fully Priced?

Advertisement Recent IDWeek data keeps Pfizer’s infectious disease engine in focus Pfizer (PFE) is putting its infectious disease research front and center, p...

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.